EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway

Xianwei Zhou, Chu Qiao, Xuehui Chu, Yajing Yang, Haoran Man, Jingxin Liu, Yunzheng Li, Zhu Xu, Huan Li, Xiaodong Shan, Zaowu Lian, Yanjun Lu und 4 weitere

Cellular Oncology · 2025

DOI: 10.1007/s13402-025-01087-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Xianwei Zhou und 15 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Model Animal for Disease Study, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing D…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, STAT3 Transcription Factor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsSTAT3 Transcription FactorDrug Resistance, NeoplasmB7-H1 AntigenCalgranulin BImmunotherapyPoly (ADP-Ribose) Polymerase-1Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansAnimalsCell Line, TumorSignal TransductionMiceMice, NudeProteolysisMice, Inbred BALB CGene Expression Regulation, NeoplasticProteasome Endopeptidase Complex

Stichwörter der Autor:innen

Hepatocellular carcinomaImmunotherapyPoly (ADP-ribose) polymerase 1Programmed Death-Ligand 1S100 calcium-binding protein A9

Substanzen

STAT3 Transcription FactorB7-H1 AntigenCalgranulin BPoly (ADP-Ribose) Polymerase-1Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCD274 protein, humanS100A9 protein, humanSTAT3 protein, humanPARP1 protein, human

Autor:innen und Institutionen

  • MOE Key Laboratory of Model Animal for Disease Study, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing Uni…
  • MOE Key Laboratory of Model Animal for Disease Study, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nan…
  • Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
  • Department of Hepatobiliary Surgery, Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of Anhui M…
  • Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Affiliated Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, 210008, China.
  • Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210008, China.

Zitieren

APA

Zhou, X., Qiao, C., Chu, X., Yang, Y., Man, H., Liu, J., Li, Y., Xu, Z., Li, H., Shan, X., Lian, Z., Lu, Y., Wang, W., Yu, D., Sun, X., & Li, B. (2025). S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway. Cellular Oncology. https://doi.org/10.1007/s13402-025-01087-0

Vancouver

Zhou X, Qiao C, Chu X, Yang Y, Man H, Liu J, et al. S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway. Cellular Oncology. 2025. doi:10.1007/s13402-025-01087-0

BibTeX
@article{Zhou2025,
  author = {Zhou, Xianwei and Qiao, Chu and Chu, Xuehui and Yang, Yajing and Man, Haoran and Liu, Jingxin and Li, Yunzheng and Xu, Zhu and Li, Huan and Shan, Xiaodong and Lian, Zaowu and Lu, Yanjun and Wang, Weihong and Yu, Decai and Sun, Xitai and Li, Binghua},
  title = {S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-025-01087-0}
}
Kostenlos starten →